Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

nsforming the therapeutic antibody space. The speed and productivity of our first three internal programs have enabled us to begin discovery work on two new therapeutic targets. These developments have been instrumental in attracting companies seeking a reliable, robust platform for generation of therapeutic grade antibody candidates. Given this progress, I am excited about arGEN-X' prospects for the coming year."

Note for the editor

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody™ platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its platform on four human disease targets to date and has broad patent claims in place covering its technology.

arGEN-X' SIMPLE Antibody™ Platform is based on the active immunisation of Camelids with target antigens to deliver antibody variable regions that are perfectly matched to those of human antibodies. The combination of those variable domains with the constant domains of human antibodies, generates full size, human therapeutic antibodies.

The SIMPLE Antibody™ Platform enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

For further information, please contact:


  
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... , July 24, 2014 Amgen (NASDAQ: ... quarter financial results on Tuesday, July 29, 2014, after the ... followed by a conference call with the investment community at ... be Robert A. Bradway , chairman and chief executive ... Live audio of the conference call will be simultaneously ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists who ... do to ensure that their practice will be a success. ... basic supplies they use the most can make all the ... dentists have recently discovered that purchasing discount dental supplies ... According to successful dentists across the ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
... 1, 2012 The FDA and representatives from the ... on proposed recommendations for the third reauthorization of a ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The recommendations would authorize the ... five years, plus adjustments for inflation. Details of the ...
... Corporation (NYSE: BSX ) announces first ... PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent ... the new device was performed by Professor Antonio ... at Columbus Hospital and San Raffaele Hospital in ...
Cached Medicine Technology:FDA and Industry Reach Agreement in Principle on Medical Device User Fees 2FDA and Industry Reach Agreement in Principle on Medical Device User Fees 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 3Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 4
(Date:7/25/2014)... The North America Artificial lift market report ... with analysis and forecast of revenue. The artificial lift market ... billion in 2013 to around $7 billion by 2018, at ... Browse through the TOC of North America artificial lift market ... also provides a glimpse of the segmentation in North America ...
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir ... Zoom Whitening is one of the most powerful whitening treatments ... professional. This light-assisted treatment uses a prescription-strength gel that can ... to break up stains that are in both the enamel ... soft drink and tobacco stains. , About Dr. Amir ...
(Date:7/25/2014)... July 25, 2014 The rising pharmaceutical sale ... to the growth of the US PBM industry. A slow ... value of pharmaceutical sales in the US over the past ... attributed to rise in the prescription volume over the past ... Benefit Management (PBM): 2013 Edition” the demand for the pharmacy ...
(Date:7/25/2014)... 25, 2014 Ross A. Clevens, MD, ... invited to join the exclusive Obagi Clinical Advisory Board, ... plastic surgeons, plastic surgeons and dermatologists. , Dr. ... Advisory Board of thought leaders held its first meeting ... was to give Obagi the opportunity to meet with ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Dietary changes ... gut on a daily basis, according to a new ... systems that might help detect and ease flare-ups for ... disease (ulcerative colitis and Crohn,s disease), the researchers said. ... but their effect on human health isn,t well understood, ...
Breaking Medicine News(10 mins):Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... 10 The Community Oncology Alliance (COA) today issued a ... their practices if critical Medicare reimbursement fixes for treating cancer ... reform. , "Current health reform legislation before Congress does not ... in January to cancer care," said Patrick Cobb, ...
... , SACRAMENTO, Calif., Dec. 10 ... California Affiliates of Susan G. Komen for the Cure® signaled ... Every Woman Counts program, which would effectively shut ... low-income and uninsured women for the first six months of ...
... A never-approved drug developed to prevent the death of nerve ... keeping normal cells healthy and intact, an international team led ... journal Breast Cancer Research . Prof. Malka ... stroke drug a member of a family of phenanthridine ...
... ... Laser-type device to be ... San Diego (PRWEB) ... jointly entered into a letter of intent with Advanced Light Devices to develop a proprietary laser system. It ...
... , SILVER SPRING, Md., Dec. 10 The U.S. ... approved to replace a portion of plasma used when storing ... donor plasma to be used for other purposes. , (Logo: ... platelets, which are blood components that help with blood clotting, ...
... SALEM, Ore., Dec. 10 West Coast Bank,s Salem Battle Creek ... hospitalized at the Salem Hospital Pediatric Wing and Neonatal Intensive Care ... branch, 5686 Commercial St. SE, Suite 110 on week days from ... Manager of Pediatrics at Salem Hospital said, "The hospital is in ...
Cached Medicine News:Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 4Health News:California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 2Health News:California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 3Health News:Finding the Achilles' heel of cancer 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 3Health News:FDA Approves First Additive Solution for Platelet Storage Up to 5 Days 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: